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ABSTRACT
A study of platelec aggregation and MDA production 
after an oral dose of 300mg aspirin indicated that 
partial recovery of platelet function occurred when 
approximately one third of the circulating platelets 
had been replaced by new (uninhibited) platelets.
In vitro studies on mixtures of normal and aspirin 
inhibited platelets indicated partial restoration of 
platelet aggregation and thromboxane production 
with as little as 10% of normal platelets in some 
subjects. Restoration of full function required a 
higher proportion of normal platelets. There was 
considerable variation between subjects. These data 
suggest that complete suppression of platelet functions 
in all normal subjects requires daily administration of 
the drug.
Despite the hyperaggreg&bility of platelets in Familial 
Hypercholesterolaemia/ ISO mg aspirin was shown to 
inhibit platelet aggregation to the same e.ttent as 
occurs in normals.
Theoretical considerations suggest that an ideal dose 
of aspirin would be one that Inhibits platelet 
aggregation without affecting prostacyclin production 
by vascular endothelium and thus causing a shift in the
TXA2 :PGl2 balance. A dose of 40mg may be too high 
since daily doses way be cutnti’ ive and suppress both 
PGI^, and TXA2* Although daily doses of 2Qmg 
aspirin inhibits thromboxane production with no effect 
on vascular prostacyclin this dose does not adequately 
inhibit platelet aggregation. Therefore when 
monitoring threshold doses for low dose aspirin/ 
platelet aggregation tests seem to be mandatory.
The concept of a low dose of aspirin ^ that would 
discriminate between the inhibitory effects on 
platelets and on the endothelium/ although attractive/ 
may well be illusory.
Dietary manipulation of platelet fatty acids, which is 
an attractive alternative to pharmacological 
suppression of platelet function/ revealed the 
following: After daily ingestion of 300-400g sardines, 
pilchards/ herring and/or kabeljou which supplied l~4g 
EPA and elimination of AA containing foods - the ratio 
of eicosapentaenoic EPA to arachidonic acid (AA) in 
the platelet increased. This was accompanied by a 
decrease in platelet aggregation to ADP, epinephrine, 
collagen and a decrease In thromboxane B2 
production. Serum and HDL cholesterol levels fell 
significantly but LDL and triglyceride values did not 
change,. Elimination of dietary AA without addition of
EPA did not inhibit platelet aqqreqation or thromboxane 
production. Cftanqes in platelet function were 
therefore attributed to the increase in dietary e p .A,
Dietary supplementation with 1, 8q MaxEPA showed no 
reduction in plat«ltt aqqreqation responses despite an 
incr»A«« in plac*l*t E M .  Bleeding tiroes were 
prolonged in th« m m m c m  of .any change in platelet 
tifnction, S*vu« HDL, eholeisfctrol was increased and 
trlgAyeerid## r«due*d» Th*dft finding® suggest tLat the 
iwehiwla#* toy which SPA-rich fith oil -influences primary 
r*<}ttir*4 r*~»valu*tion. This study remains: 
co»patiftl* with thm proposition that dietary fish or 
Ci*J* oil d®i«ya print* ry fta##tosca*iit and influences 
*®rr«» lipids*- «n<s may d«cr«a«® the incidence of 
arterial tftroettoftis in the hw««n population* The 
*«chanla* of this effect has not yet been determined.
EPA did not inhibit platelet aqqreqatiorj or thromboxane 
production. Chanqes in platelet function were 
therefore attributed to the increase in dietary EPA.
Dietary supplementation with 1, Bq HaxEPA snowed no 
reduction in platelet aqqregafcion responses despite an 
increase  in p ia t e ie t  SPA* BXeedinq t in ea  were 
prolonqed in the attsenee o f  any chanqe in p la t e le t  
ftfttetian* Sertm HOI* c h o lestero l  was Increased and 
t r iq ly c a r id e a  reduced , These  f in d in q a  avqqeat that th* 
*echai»i«»  by which £PA-rich f i s h  oil -.influences primary 
haem ostasis  req u ires  r*~ *valtiatlon . If hi® study remains 
co w p atibls  w ith  the proposition that d ie t a r y  fish or 
f i s h  o il  delay s  primary hsettostasi* and in f lu e n c e s  
i»rw« lipids# and way deers*?*# th* in c id ence  of 
a r t e r i a l  throMhosis in  th *  human p o p ulatio n *  The 
m echanis* of this a f f e c t  has not yet  been d eterm ined .
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CHAPTER
1. GENERAL INTRODUCTION
1.1. The role of platelets in haemostasis and thrombosis 
Under normal circumstances, the platelet circulates in the 
blood for approximately 10 days aa a disc shaped cell that 
is non-adherent to other platelets? cellular elements, or 
the vascular endothelium (Triplett, 1978; White, 1983). 
Johnson et a l .,(1967 ), defined haemostasis as the arrest 
of bleeding from a breach in the wall cf a blood vessel/ 
and it required simultaneously the presence of adequate 
numbers of normal, circulating platelets and a normally 
functioning coagulation system. The reaction of the 
platelet to a damaged vessel wall is similar whether the 
damage is traumatic or a result of the atherosclerotic 
process (Fhilp, 1981). When there is endothelial damage, 
platelets rapidly adhere to the exposed subendothelial 
surface (Preston and Greaves, 1985). In most of the 
studies in normal animals, there has been little evidence 
of thrombus formation on the autoendothelium of large 
arteries in areas of undisturbed flow (Mustard et a l ., 
1985). Instead, the subendothelium becomes covered with a 
carpet of platelets with some platelet aggregates in a few 
areas such as at vessel orifices and branches (Groves 
et a l ., 1979). A d h e ^ o n  of platelets to the 
subendothelium appears to be largely independent of blood 
coagulation since the formation of the platelet carpet is 
not significantly inhibited by heparin at concentrations
that inhibit the coagulation process (Groves et a l . /1982 ) .
When the endothelium is removed from areas where blood 
flow is disturbed platelet aggregates and platelet-fibrin 
thrombi form on the subendothelium of apparently normal 
blood vessels (Mustard et a l ., 1985), The extent of 
thrombus formation is probably the result of a balance 
between the factors causing thrombus formation and those 
causing dissolution* The patterns of blood flow obviously 
affect platelet accumulation: for example/ platelets 
accumulate in vortices. The force of blood flow may also 
disrupt thrombi (Mustard et a l ., 1985 ), There have been 
very few detailed studies of the interaction of the 
various factors that lead to the formation of thrombi. 
Occlusive thrombi rarely form unless blood flow is 
considerably disturbed and the vessel is narrowed/ as at a 
stenosis (Folta et a l ., 1982),
The roles of plasma proteins in platelet adherence to the 
subendothelium are of considerable interest. The 
observations concerning fibronectin are confusing. From 
some studies it has been suggested to be the receptor for 
collagen on platelets (Bensusan et a l «, 1978) or to 
promote platelet interaction with collagen (Grihell 
et a l ,, 1979), In other studies/ fibronectin has not been 
found necessary (Sochynsky et a l ,, 1980) and in some 
experiments, preincubtion of fibronectin with collagen has 
been reported to inhibit platelet interaction with
collagen (Bensusan et a l ., 1978). Following adhesion, the 
platelets undergo a secretory process/ during which 
substances found in the alpha granules and dense bodies 
(ADP# serotonin/ beta-thromboglobulin, platelet factor 4) 
are secreted from the cell. This is known as the release 
reaction (Grette/ 1962). Thus, exposure of 
sub-endothelial structures results in adhesion of 
platelets/ release of their granular constituents, 
aggregation/ and the interweaving of the platelet 
haemostatic plug with fibrin filaments and the arrest of 
bleeding (Philp, 1981)
1.1.1. Platelet adhesion and shape change 
Upon adherence to the sub-endothelium/ dramatic 
morphological changes occur in platelets, and these are 
similar to platelet responses which can be induced in 
vitro by connective tissue particles, tumor cells, 
bacterial/ or purified collagen. Dendritic pseudopodia are 
thrown out by the adhering platelets, multivesicular 
membranous sacs appefcf in the terminal bulb of the 
paeudopodia/ and these become swollen, eventually 
rupturing and releasing their contents to the surrounding 
medium It has been postulated that this represents the 
physical manifestation of the release reaction (W&rren and 
Vales, 1972). The initial adhesion is followed quickly 
by a change from the circulating, discoid shape of the 
platelet to a spiny spherical configuration and the
5centralization of granular <!onsti tuents (Scarborough 
et a l ,, 1969),
1.1.2. Platelet aggregation
Platelet to platelet aggregation follows platelet 
adhesion. Platelet aggregation can be measured 
ifcurbidometric&lly with a platelet aggregometer (Born# 
1962). The aggregometer is basically a photo optical 
instrument that is connected to a strip recording chart. 
h cuvette of platelet rich plasma is placed in the path of 
a beam of light and is stirred, so that the diffusa cloud 
of tiny platelets scatters the light and prevents much of 
it from reaching a photocell on the other side of the 
transparent tube. The transmittance of light relative to 
a platelet poor blank/ is recorded. When an aggregating 
agent is added/ the platelets clump together/ allowing 
more light to pass through the suspension, h tracing of 
the amount of light reaching the photocell provides a 
continuous record of the course of platelet aggregation. 
Aggregation agents such as ADP/ thrombin/ collagen/ 
epinephrine and arachidonic acid induce platelet 
aggregation .
1.1.2.1. ADP induced aggregation
ADP may be derived from endothelial cells (Born/ 1985) 
erythrocytes (Gaarder et a l ., 1961) or platelets (Harms,
1978). In 1962/ Born reported that of 22 nucleotides
6tested/ only ADP and deoxyadenosine diphosphate induced 
the aggregation of platelets, and that adenosine 
monophosphate (AMP)/ ATP and adenosine were capable of 
inhibiting ADP-induced aggregation. The aggregation of 
platelets by ADP wa3, moreover/ concentration dependent.
A biphaaic aggregation response/ that is, a primary and 
secondary wave of aggregation, is induced by low 
concentrations of ADP. At very low levels only a ^iniary 
wave will be observed, followed by disaggregation. At 
high concentrations a single broad wave will occur (Born/ 
1962). in 1964, Cross et a l ., suggested that ADP might be 
involved in platelet aggregation induced by a variety of 
stimuli. They showed that adenosine inhibited platelet 
aggregation induced not only by ADP but also by 
adrenaline, noradrenaline, serotonin, and thrombin,
Gaarder and Laland (1964), demonstrated that ADP was not 
taken up into ceil cytoplasm but appeared rather to be 
associated loosely with the platelet •nambrane, and 
suggested the existence of a membrane receptor for ADP. 
Hampton and Mitchell (1966) using ADP induced changes in 
the electrophoretic mobility of platelets, estimated 
binding sites at 0,85 x 10 pet platelet. Lips and 
Sixma f1977) studied the uptake of i4C ADP by isolated 
human platelet membranes and found both high and low 
affinity binding sites. The former was calcium dependent 
but not temperature dependent, and had an optimum pH of
tested/ only ADP and deoxyadenosine diphosphate induced 
the aggregation of platelets, and that adenosine 
monophosphate (AMP), ATP and adenosine were capable of 
inhibiting ADP-induced aggregation- $he aggregation of 
platelets by ADP was, moreover, concentration dependent,
A biphasic aggregation response, that is, a primary and 
secondary wave of aggregation, is induced by low 
concentrations of ADP. At very low levels only a primary 
wave will be observed, followed by ai^gyreaation. At 
high concentrations a single broad wav® will occur (Born, 
1962) . In 1964, Cross et a l ,, sugg^tu^ that ADP might be 
involved: in platelet aggregation by a variety of
stimuli. They showed that adenosine xnnl'oi'tx^ platelet 
aggregation induced not only by ADP but al;w by 
adrenaline, noradrenaline, serotonin/ and thrombin,
Gaarder and Laland (1964), demonstrated that imp ftot 
taken up into cell cytoplasm but appeared rather to to© 
associated loosely with the platelet membrane, and 
suggested the existence of a membrane receptor for ADP. 
Hampton and Mitchell (1966) using ADP induced changes in 
the electrophoretic mobility of platelets, estimated 
binding sites at 0,85 x 105 per platelet. Lips and 
Sixma (1977) studied the uptake of 14c ADP by isolated 
human platelet membranes and found both high and low 
affinity binding sitea. The former was calcium dependent 
but not temperature depr .dent, and had an optimum pH of
7.3. Born and Cross (1964) have reported a requirement
*\* 4* *4*4*
for extra-cellular Ga or Mg and the presence of 
such divalent cations has been claimed as an essential 
requirement for human platelet aggregation 
(r,uschet,1985).
1.1.2.2 Thrombin Induced aggregation 
Thrombin-induced platelet aggregation and secretion 
involves the participation of specific binding sites on 
the platelet membrane,(Phillips and Agin, 1974). The 
process appears to be pH dependent but energy independent 
(Hattey and Binaer, X979) and inducers a permanent 
alteration in membrane configuration (Subbarao and Kakkar, 
1979). The arachidonic acid metabolic pathway does not 
appear to play an essential role (Leband and Simons,
1979). Kinlough-Rathbone et al., (1977) suggested that 
thrombin was capable of inducing aggregation by different 
mechanisms, with low concentrations involving ADP release 
and the participation of the arachidonic acid pathway and 
higher concentrations utilising another system, possibly 
involving internal shifts of ionic calcium. Fujimura 
et al., (1980) speculated that thrombin binds to the 
platelet surface membrane glycoprotein (GP)1 and 
hydrolyzes GPV specifically, and that the hydrolyzed GPV 
might act as a signal to induce the platelet release 
reaction.
1.1.2.3. Collagen Induced aggregation
Platelet activation and release induced by collagen is a 
complex process which appears to involve more than one 
mechanism. It has been suggested by Huzoor-Akbar and 
Ardlie (1976) that one mechanism involves a direct effect 
on platelets and the other is mediated via thrombin. 
Kinlough-Rathbone et al., (1977), showed that collagen 
could aggregate platelets which had been previously 
degranulated by thrombin, and in a medium which contained 
creatine phosphate/creatine phosphokinase which converts 
available ADP to ATP. This aggregation was inhibited by 
aspirin and indomethacin, indicating that in the absence 
of extracellu;.,*c , collagen aggregation can be mediated 
through -.h*} ars?*udonic acid pathway* Recently using 
stispendeu pretreated with pyridoxal 5 ’-phosphate
(biologic^; - «i«*vive coenzyme form of pyridoxine or 
vita'dr ’-'g wrtiu'M r-ucta with free amino groups) and
Krishnvw.uurthi and Kakkar (1985), have suggested 
that collagen induced aggregation may also be via the same 
mechanism/receptor as that used by ADPt but platelet 
adhesion seems to involve a distinct <chanism/receptor 
that is not affected by pyridoxal 5 '-phosphate. Thus,
Cree amino groups on the platelet membrane may be involved 
In the induction of platelet aggregation by collagen, but 
not platelet adhesion to collagen. Collagen induces only 
a single wave of aggregation, which corresponds to the 
release reaction of platelets. This is characterized by a
lag period before aggregation begins (Wilner et al./1968) .
1.1.2.4. Epinephrine induced aggregation 
Epinephrine produces a biphasic pattern of aggregation 
(MacMillan/ .1966; O'Brien, 1966)/ with the release of 
granular constituents. Epinephrine has been reported by 
some investigators to induce the uptake of calcium by 
platelets (Owen et al., 1980; Owen and LeBreton 1980).
In contrast, others have been unable to demonstrate 
effect of epinephrine on calcium uptake (Brass and 
Shattil, 1982‘ Clare and Scrutton/ 1984; Lalau Keraly et 
al., 1985) except in circumstances in which the release 
reaction occurs (Clare and Scrutton, 1984). The uptake of 
epinephrine by the platelet appears to involve an 
adrenergic receptor since the effect on platelets can be 
blocked by -adrenergic blocking drugs such as 
phentolamine (Qppenheim and Youdin 1979; Lalau Keraly 
et al., 1985), However inhibition of the p-receptor 
potentiates the action of epinephrine in inducing 
aggregation of platelets that are refractory to ADP (Kerry 
and Scrutton/ 1983; Lalau Keraly et al , / 1985) and 
supports the view that the effect of ephinephrine is 
probably dependent upon the balance of ©<, and p receptor 
stimulation (Kerry and Scrutton 1983). In view of the 
actions of epinephrine on the adenylate cyclase system («K 
receptor agonist Inhibit adenylate cyclase; j3 receptor 
agonists stimulate it/ Scrutton and Wallis/ 1981) it may
10
be that at least part of the action of epinephrine is 
mediated through adenylate cyclase, The report by Figures 
et al, / (1984) that epinephrine increases the binding of 
ADP to platelets, indicates that this has to be considered 
as another pathway by which epinephrine may exert its 
effect on platelets*
1.1.2.5. Arachidonic acid induced aggregation 
Arachidonic acid (AA) is a free fatry acid that induces 
both platelet aggregation and prostaglandin synthesis. AA 
is one of the major fatty acids in human platelets. It is 
present in both intracellular granules and in membrane 
compartments, mainly esterified to the phospholipid 
fraction, and is the precursor of thromboxanes and hydroxy 
fatty acids (Marcus, 1982), Arachitfonate cannot be 
transformed unless it is hydrolyzed from phospholipid and 
made availaole in free form (Marcus, 1978). Recent 
evidence indicates that AA is liberated from platelet 
phospholipids by a dual mechanism. The first involves the 
combined action of a phosphatidyl inositol-specific 
phospholipaae C (Rittenhouse^Simmonst 1979), followed by a 
diglyceride lipase (Beil et al., 1979), thereby yielding 
frpe AA. in addition there appeals to be a phospholipase 
A2 type of activity liberating AA from phosphatidyl 
ethanolamine (Broekman et al., 1980). Recent evidence 
indicates that phosphatidyl inositol may be the major 
source of AA in the platelet (Rittenhouse-Simmons, 1979;J
Guichardant and Lagarde, 1980; Broekman et al. / 1980).
When arachidonic acid is added to platelet rich plasma the 
phoapholipase step is by passed and cyclooxygenase is 
activated directly. A normal shape change and full 
aggregation response ensue. The arachidonate is 
transformed to thromboxane &2 (tXA2), which may 
directly mobilise calcium which then inhibits adenylate 
cyclase and platelet cyclic AMP levels fall. In addition 
ADP and serotonin are released from platelet dense 
granules. TXA^ is also released and together with ADP 
serves to 'recruit' other platelets, ie. the released 
ADP and TXA2/ aggregate other platelets in the 
surrounding medium (SiJv©r et al./ 1973; Marcus 1979).
1.1.3. Platelet secretion or release 
The secretory process or release reaction was first 
described by Grette (1962) and is the selective extrusion 
of stored platelet constituents. It is essentially a 
process of exocytosis and resembles the secretory 
mechanisms of endocrine cells (Hovig> 1962). Day and 
Holmsen (1971) termed the release of the constituents of 
dense granules Release I? and that of both dense and «< 
granules Release II TMie release of »<.-granules does not 
occur in the absence of dense body release.
Dense granules or dense bodies have been shown to contain 
adenine nucleotides (ADP/ ATP and GTP) (Day and Holmsen,
1971)/ serotonin and calcium (Salganicoff et al. / 1975). 
Dense granule release (Release 1) is induced by high 
concentrations of ADP and epinephrine and low 
concentrations of thrombin and collagen, and leaves e<~ 
granules intact (Day and Holmsen, 1971). It proceeds 
quicker than <*.-granule secretion. Platelet factor 4 has 
been reported to be .located in dense granules (Youssef and 
Sarkhan/ 1968). The release of oC-granule contents 
(Release II) is induced by thrombin and collagen (Holmsen 
et al.; 1977)*
Packham et al., (1977) classified a large number of 
aggregating agents according to their mechanism of action/ 
their ability to induce release/ and their dependence upon 
released ADP and prostaglandin endoperoxide formation.
According to their scheme/ group I agents aggregate 
platelets without inducing the release reaction or 
endoperoxide formation? even when present in high 
concentrations* These would include serotonin in platelet 
rich plasma (PRP)/ sodium periodate in a medium without 
glucose/ and ADP in a medium containing physiological 
concentrations of calcium ions and protein. Under these 
circumstances only the initial wave of aggregation would 
be observed.
Group 2A agents cause the initial wave of aggregation, 
which is independent of released ADP or endoperoxide 
formation but, in sufficient concentration and in a 
suitable medium, will induce a second wave of aggregation 
with endoperoxide formation and the release of ADP. These
4 * 4 *
would include ADP in citrated PEP or in a low Ca 
mediumi adrenaline and noradrenaline in PRP and
vasopressin in heparinised PRP or in an artificial medium
with calcium and fibrinogen , free radicals of 0^ and OH
in an artificial medium. Group 2B agents are
agglutinating substances, The term agglutination as
distinct from aggregation, is reserved for those agents
which form bridging complexes between platelets. This
group includes ristocetin/ bovine factor VIII and
polylysine in citrated PRP, lectins and concanavalin A in
an artificial medium. A second wave of aggregation with
release of ADP and endoperoxide formation occurs which is
blocked by EDTA,
Group 3 agents do not induce primary aggregation but 
induce release, with secondary aggregation occuring as a 
consequence of the release of ADP and endoperoxide 
formation. The aggregation inhibited by EDTA. This 
group includes collagen# arachidonic acid, antigen*- 
antibody complexes, and foreign surfaces such as latex 
particles. Group 4 agents are similar except that they 
involve further mechanisms which can cause aggregation and 
release independent of the release of ADP and endoperoxide
*#•
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formation. These include proteolytic enzymes such as 
thrombin and trypsin? calcium ionophore A23/1S7/ and 
Newcastle Disease Virus.
1,1.4. Platelets and prostaglandins 
The demonstration that intact platelets or platelet 
homogenates were capable of synthesizing PGH2 + pgG2 
from exogenous arachicionic acid (Glenn et al., 1972) and 
that arachidonic acicl induced platelet aggregation when 
added either to washed platelets or platelets in plasma 
(Silver et al., 1973? Marcus 1979)/ whereas other 
unsaturated fatty acids did not/ provided evidence for an 
important role for the arachidonic acid pathway in the 
regulation of platelet function,,
In 1974/ Hamberg and Samuelsson demonstrated that two 
endoperoxide intermediates, PGG2 and PGH2* were 
produced during prostaglandin synthesis in platelets and 
were potent ini ciators of platelet aggregation. In 1975/ 
Hamberg, Svensson and Samuelsson, identified a substance/ 
thtfombo^ane A^ (TXA2)/ which was an intermediate 
between PGG2 and the inactive end product thromboxane 
and which was even more potent than the endoperoxides 
in inducing platelet aggregation.
The biochemical pathways involved in the formation of 
prostaglandins and thromboxanes have been thoroughly
reviewed by numerous authors (Needleman et a!.# 1976; 
Moncada and Vane/ 1978? Marcus 1978? Philp# 1981;
Holmaen and Karpatkin# 1983). Characteristically# in 
platelets as in other cells, prostaglandins are not stored 
but are synthesized rapidly in response to an appropriate 
stimulus* Initially# the enzymes phospholipatu c and 
phospholi pase A release arachidonic acid from membrane 
phospholipids (principally phosphatidylinositol and 
phosphatidylethanolamine respectively)# 
(Rittenhouae-Simmons, 1979; Broekman et al*# 1980). 
Thrombin# platelet activating factor# collagen and 
arachidonic acid induce the activation of phospholipase C 
during shape change of human platelets (Siess et al.# 
1983a; Siesa et al., 1983b; Lapetina and Siegel 1983;
6t al•t 1984). Phospholipase C activation generates
1,2 dlacylglyerol# which stimulates protein kinase C# and 
leads to formation of phosphatidic acid myo-inositol 
1,4/5#--triphosphate/ which has been Implicated in 
intracellular ca f+ mobilization (streb et al. # 1983)*
The arachidonic acid made available by the phospholipase 
may enter wither the lipoxygenase pathway or the 
cyelooxygenase pathway.
Lipoxygenase pathways under the action of the 
lipoxygenase enzyme # arachidonic acid may be converted to 
the non prostanoic structures 12L~hydroperoxy-5 # 8 #10 #14-* 
eicosatetraenoic acid (HPETE) and thence by a peroxidase#
,__r.... . f . dt__tj&f-
reduced to laL-hydroxy-S , 8/10 / 14-eic’*?atetraenoic acid 
(HETB). HPKl'K can also be transformed into the 
leukotrienes.
Cyclooxygenase pathway; the enzyme cyclooxygenase 
converts aeachidonic acid to the endoperoxides pgg2
which, by peroxidase converts to PGH^. Ths* 
endoperoxides may either be converted by thromboxane 
synthetase to thromboxane which, being unstable, is 
hydrolyzed to thromboxane B2, converted to the stable 
prostaglandins PG!$2; PGD^ (either enzymatically by an 
isomerase or non-enzymatically) and PGP2 (enzymatically 
by a reductase)/ or converted to 12L / 5/8 / 10*•hepta••' 
decatrienoic acid (HHf) and malondialdehyde (MDA). A 
summary of the biochemistry of the Ah metabolic system is 
shown schematically in fig (1.1)*
In the vascular endothelium/ PGH^ is converted to 
prostacyclin (FGI^ ,) an antiaggregatory agent*, and 
vasodilator (Moncada et al., 1976)* PGI2 was shown to 
be many times more potent at inhibiting aggregation than 
<?iither PGR^ or PGD2* is thought to cause the
general inhibition of platelet aggregation, adhesion 
(Fr*' ‘ and Barton, 1977) and the release reaction (Gorman 
et al., 1977 ) by activating platelet membrane adenylate 
cyclase (Gorman et al., 1977; Dateson et__ a_l *, 1977 ) and 
thus causing an increase in the intracellular level of 
cyclic AMP (Best et al*, 1977).
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Pig. 1,1. The biochemistry of arachidonic auid in platelets (adapted from 
Philp 1981? Holmsen and Karpatkin, 1983)
1.1,5* The regulation of Platelet Function 
A number of schemes for the regulation of platelet 
function with minor variations have been formulated 
(Gerrard and White, 1978 5 Gorman et al», 1979; Philp 
1981; Luscher 1985; Siesa et al., 1985) „ One such scheme 
is shown in fig 1*2, According to current concepts, 
proaggregatory agents such as thrombin, collagen/ ADP, 
epinephrine etc, interact at the surface of the platelet 
membrane with a receptor# which is probably a 
phospftoryl&ted protein in most instances and which way or 
may not be a calcium binding protein. Stimulus receptor 
interaction dephosphorylates the protein and releases 
bound calcium/ which stimulates the formation of 
diacylglycerol -nd phoaphatidic acid, indicating the 
activation of phopholipase c. Th£s sets in motion the 
araehidonie acifc (M) caacads. The formation o£ *XA2 
provides the physiological calcium ionophore to mobilize 
additional Ca from various storage sites (Philp,
1981). TXA2 Shan ralaasas ca++, either through
4*4*conversion to TXB^ or by exchange with Mg , and 
Ca inhibits adenylate cyclase (AC) (Luscher, 1985 } / 
lowering cyclic adenosine monophosphate (cAMP) levels and 
removing any inhibitory effect of cAMP on phospholipase C 
and cyclooxygenase. Thus a positive feedback mechanism is 
set in motion to accelerate the A A cascade. The free 
calcium also activates excitation ** contraction ~ 
secretion coupling, resulting in centralization and the
Subsequent extrusion of dense granules. An 
antiaggregatory stimulus (fJ«) such as POX^/ ^
adenosine, acting upon specific receptors on the membrane 
surface/ activates adenylate cyclase (AG) which forms cAMP 
from ATP» cAMP activates a protein kinase which 
phosphorylates a protein believed to promote Ca** 
re-uptake and hence maintain a low level of free Ca++.
CAMP also ihibits phospholipases and cyclo-oxygenase, thus 
inhibiting $XA2 formation, fhe s^ tiori of various 
inhibitors of platelet aggregation can now be viewed in 
the light of their ability to prevent the mobilization of 
intracellular Ca++* Thus inhibitors of cyclooxygen'-ise or 
thromboxane synthesis would limit the ability of the 
ttlolu* lonopho*. *xa2. scimiila o n  of AC or inhibitors 
of phosphodiesterase promote the uvulas ion c m v  
which inhibits phosphnlipase A2 cyeloo^ygenase and 
which may promote the compartmentalia^tlon of Ca++.
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Fig. 1*2* A scheme foe the regulation of platelet 
function (Adapted from Bhilp, 1981),
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1*1.6. Platelets? eho vessel wall ana thrombosis 
Experimental studies suggest that it is likely that 
platelets are important in the initiation and progress;on 
of arterial thromboembolic disease (Lowe? 1981? Preston 
and Greaves, 1385), Activation of platelets is associated 
with physico-chemical changes which, under some 
conditions, encourag atelet-platelet and platelet- 
vessel wall interactx-uns* These changes may be associated 
with activation of other haemostatic mechanisms which may 
ultimately yivfe rise to platelet-fibrin thrombi (Preston 
and Greaves, 1$8$).
Within the circulationt the association between platelets 
and arttrie« is encouraged by the rheaiogical properties 
o£ arterial tkleod/ the flow of which tends to direct the 
platelets towarefs the vessel milt particular!'* at 
arterial bifurcations and right angled junctions (Murphy 
et al.f 1962}, Endothelial cell damage at these sites, 
occasioned by haemodynamic stresses/ causes the 
sutoendotfteHal elements to be exposed* Local arterial 
thrombus formation is thus encouraged? since platelets 
avidly adhere to these elements (Preston and Gruaves? 
1985).
In addition ? platelets may make an important contribution 
to the development of atherosclerosis, as first proposed 
in 1842 by Rokit&nsky (cited by Born, 1985). There are at
least three mechanisms by which platelets may participate 
in atherogenesis. First/ through damaging arterial 
endothelial cells by releasing injurious agents, 
presumably where circulating platelets adhere (Mustard 
et al. i 1977). Secondly through the release in such 
situations of a factor responsible for smooth musela 
proliferation in the arterial wall (Ross and Glomset, 
1973). thirdly, through the formation of persistent 
mural thrombi, which are organised into intimal 
thickenings (Walton* 1975), underlying all three claims 
is the assumption that some normal circulating platelets
* *■«
settle on arterial walls for long enough to release some 
of their contents (Born, 1985). These considerations have 
led to attempts to influence the course of thrombotic and 
atherosclerotic disease by the use off drugs which reduce 
platelet reactivity. Arguably, the most important of 
these is aspirin (Preston and Greaves, 1985).
in years the effects of prostaglandin endoperoxides
on the interaction between platelets and the vessel wall 
have received much attention (Moncada and Vane, 1978? 
Bunting et al.,1983; Moncada, 1985). prostaglandin 
endoperoxides are at the cross roads of AA metabolism, for 
they are tsho precursors of substances with opposing 
biological .otlviti.a. On the one h.nd, produced
by the platelets is a strong vasoconstrictor, induces the 
release of ADP from dense granules and decreases cyclic
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adenosine monophosphate (cAMf>) and hence stimulates 
platelet aggregation. On the other hand f prostacyclin 
produced toy the vessel wall is a strong vasodilator and 
increases <jAHF levels and hence inhibits platelet 
aggregation. A ba! 'oe between pro~aggregatory TXA? and 
anti-aggregatory . 1.. has been proposed by Mon cad a and 
Vane (1978 ) and Moncada/ (1985 ). This balance could 
determine the intensity of local thrombosis and vascular 
tone* upset in this balance favouring platelet 
aggregation is postulated as predisposing to thrombosis 
(Moncada and Vane 1978; Moncada, 1985)
Several diseases have now been related to an imbalance in 
the TXAp ~ F3I^ system. Platelets from patients with 
arterial thrombosis, deep vein thrombosis, or recurrent 
venous thrombosis produce more PG endoperoxides and TXA*, 
than normal and have a shortened survival time (Lagarde 
and oechavunne, 1977). Platelets from rabbits made 
atherosclerotic by dietary manipulation (Shimamoto et al.,
1978) and from patients who have survived myocardial 
infarction (Szczeklik et al. > 1978) are abnormally 
sensitive to aggregation agents and produce more TXA^ 
than controls. Elevated TXB^ levels have been 
demonstrated in the blood of patients with prinsmetals ■ 
angina (t,ewy et al., 1979). Hirsch et al,, (1981) also 
reported increased TXB2 levels in coronary sinus blood 
of patients with unstable angina. Platelets from rats
made diabetic display an increased release of TXA^# 
whereas their blood-vessels show a reduced production of 
prostacyclin (Harrison et al.> 1978)* Platelets from 
diabetic patients are known to foe more sensitive to 
several aggregating agents (Mustard and Packham* 1977; 
Colwell et al.• 1979} and to produce more TXA^ than 
normals (Halushka et al,, 1981; DiMinno, 1985). 
Prostacyclin production by blood-vessels from patients 
with diabetes are lower than normals (Johnson et al.f
Q»»>l I*. MIHIII'.I >l
1979)/ and circulating levels of 6-keto-PGF, are 
reduced in diabetic patients with proliferative 
retinopathy (Qollery et al,, 1979)*
thrombotic thrombocytopenic purpura {TIP), like diattsrtss, is 
associated with formation of microvasculac thrombo-eraboli* 
and a deficiency in prostacyclin production may contribute 
to the increased platelet consumption that occurs in TTP 
(Bemnzzi et al», 1978 f Cocschetto et al ♦ / 1981). This 
deficiency is postulated to oe secondary to a lack of a 
"plasma factor” which normally stimulates prostacyclin 
production (MacIntyre et al., 197Q). An increased ' 
prostacyclin production< resulting from an accumulation of 
the "plasma factor" that stimulates prostacyclin 
synthesis; has been suggested to explain the haemostatic 
defect in uraemic patients (Remuzzi et al.f 1977). , 
Patients with Bartter’s syndrome excrete about four times 
as much 6-keto-PGP, as controls in the urine
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(Gullner et al., 1979), This has led to the suggestion that 
increased, production of prostacyclin mediates both the 
hyperreninaemia and the hyporesp jiveness to pressor 
agents observed in these patients (Gullner et al., 1979).
In general, it seems that, in diseases where there is a 
tendency for thrombosis to develop, TXk^ production is 
increased, or prostacyclin production reduced, or both, 
whilst the opposite is found in some diseases associated 
with an increased bleeding tendency.
1.1.7* Strategies for the manipulation q £ the TXA^:
PGi\ ratio
TKhy and represen t * in biological terms, the
opposite poles of the sarn^  general homeostatic mechanism 
for regulation of platelet aggregability in vivo. 
Manipulation of this control mechanism will affect 
thrombus and haemostatic plug formation (Moncada, 1985). 
Several pharmacological strategies have been advocated to 
manipulate the ratio of these two substances. One such 
drug, aspirin, wa used as an analgesic, an 
anti-inflammatory agent, and an antipyretic agent for many 
years before its effect on haemostasis was recognised.
Frick (1956) reported that aspirin prolonged the bleeding 
time in patients with haemorrhagic disorders. Within the 
past decade, several investigators have demonstrated that 
aspirin influences prostaglandin synthesis by inhibiting
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the initial enzyme of the biosynthetic pathway (Ferreira 
et al. i 1971’, Smith and Lands, 1971? Smith and Willis/ 
1971; Bamberg and Samuelsson, 1974; Roth et al., 1975; 
Roth and Majerus, 1975).
The therapeutic use of aspirin with regard to its platelet 
anti-aggregatory activity has been based on the hypothesis 
that increased place let:-vessel and platelet-platelet 
interactions are causative factors in the development of 
arterial and venous thrombi, as well as thromboembolic 
phenomena (Marcus, 1983)* Aspirin may serve to prevent 
these thromboembolic events, since it induces a functional 
defect in platelets/ demonstrable clinically as a 
prolongation of the bleeding time.
Biochemically this is thought to be due to inactivation 
through acetylation of the enzyme cyclooxygenase (Roth and 
Majerus, 1975) thereby eliminating the synthesis of 
thromboxane A^. Aspirin also affects the synthesis of 
PGXgf within the blood vessel wall (Villa and de 
Gaetano, 1977; Moncada, 1985)* When it was shown that 
aspirin prevented the formation of aggregatory TXAr, in 
platelets and the anti-aggregatory prostacyclin 12 in 
vascular cells - the "aspirin dilemma" emerged (Marcus 
1977; de Gaetano et al«, 1982). Inhibition of vascular 
prostacyclin production by aspirin was seen as potentially 
undesirable, Platelet cyclooxygenase was found to be
2 7
extremely sensitive to aspirin inhibition (Baenziger et 
al,, 1977) and the endothelial cell enzyme was found to be
Ilf Hl|IIW>
considerably less sensitive to aspirin inhibition than the 
platelet enzyme (Baenziger et al.. 1977; Masotti et al., 
1979; Jaffe and Weksler, 1979). This is presumably 
because the cyciooxygenase enzyme can be resynthesized by 
endothelium but not by pi&telets, which cannot synthesize 
protein (Patrono and Patrignani, 1984)* Because 
endothelial cell prostacyclin production can be resumed 
between doses of aspirin (de Gaetano et al., 1982 • Marcus, 
1983)/ the aspirin dilemma could have been easily resolved 
by administering low doses of the drug- This would tilt 
the balance in favour of prostacyclin by inhibiting 
platelet: thromboxane synthesis and sparing vascular 
prostacyclin production. Different aspirin trials to test 
this hypothesis are discussed in chapter 4.
Theoretically, the most logical way to manipulate the 
ratio, would seem to toe the induction of a 
selective pharmacological blockade of platelet thromboxane 
synthetase. These inhibitors are either derivatives of 
pyridine or imidazole. Perhaps the moat studied is 
dazoxiben, an imidazole derivative which contains a 
carboxyalkyl substituent at the l~position (Smith/ 1985), 
Some investigators have observed that dazoxiben inhibits 
arachidonic acid or collagen induced platelet aggregation 
in in vitro testa with platelet rich plasma from some
donors (responders) but not from others (non-responders) 
(Heptinstall et al», 1980? Bertele et a1., 1981; pale 
et al. / 1903; Bertele et al., 1984). In a study by Smith 
(1982) all volunteers on dazoxiberi were found to be non 
responders.
originally it was thought that these would be ideal 
antithrombotic drugs sparing PGI^ production while , 
blocking synthesis of Howeverf this is not
without consequence since a complex rearrangement of 
arachidonic acid metabolism occurs within the cell 
(Bertele et al., 1981; Tyler et al,? 1981; Vermylen 
et al»/ 1981? Smith* 1985), thromboxane synthetase (TS) 
Inhibitors allow accumulation of cyclic endoperoxides in 
platelets* The endoperoxides are potent platelet 
aggregating agents (Majerus, 1983) and t h is  l im its  the 
e ffect iv eness  o f  TS Inhibitors as p l a t e le t  suppressive agents (Preston and
Greaves, 1985), In fact/ these drugs may act primarily by 
stimulating production of platelet Inhibiting eicosanoids 
(Gorman/ 1983)* Prostacyclin production is increased by 
endoperoxld<?r steal and conversion of PGH2 to '
prostaglandin d2 (PdD^) occurs in plasma (Fitzgerald 
et al., 1983). Both prostacyclin at d PGD^ stimulate  
cAMP production in platelets and thereby inhibit platelet 
function. However, the elevations of PGI^ anc! 
are relatively modest as judged from the level of 
metabolites, and the drugs currently known have a very 
short duration of action (Fitzgerald et al., 1983). While
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the final answer will come from clinical trials, it seems 
unlikely that a drug of this class will surpass sypirin as 
an antithrombotic agent (Majerus, 1983). The ©ulphonamide 
derivative BM 13,177 blocks the thromboxane receptor on 
which endoperoxioes act/ and thus may overcome the 
limitations of thromboxane synthethase inhibitors 
(Gteeele et al., 1984), Clinical trials of these drugs 
have not yet been completed (Smith, 1985).
The search for new and more effective approaches to ,
platelet suppressive therapy thus goes on. The use of 
infusions of prostaglandin l2 \prostacyclin) has 
recently received considerable attention. Some success 
has been claimed in Raynaud's syndrome and in severe 
peripheral arterial disease (Belch et al., 1983a.bj 
Prentice et.al,, 1983) and some patients with variant 
angina may also respond (Chierchia et al., 1982). Also, 
prostacyclin infusion appears to diminish platelet loss 
during haemodialysis (Turney et al., 1980) and 
extracorporeal circulation procedures (Radegran et al,, 
1982? Aren et al., 1983). However, further controlled 
clinical trials are indicated in the broader area of 
vascular disease in order to Identify the type of patient 
who may respond to such therapy and the optimal dosage 
which should be used, stable analogues of prostaglandin
I2 have also been developed and are currently under 
trial, Xn addition, the search goes on for agents capable
of the stimulation of endogenous prostacyclin synthesis 
Varmylen, 1979).
A possible beneficial change in the balance between 
platelet ant) vascular synthesis of the oxygenation 
products of arachidonic acict can apparently be achieved by 
augmentation of the dietary .intake of the polyunsaturated 
fatty acid eicosapentaenoic acid/ an attractive approach 
to platelet suppressive therapy (Dyerberg and Bang,
1979a).
The therapeutic potential of EPA was suggested by the 
findings of Dyerberg et al., 1978), who found a 
functional substitution of EPA for AA in the diet of 
Greenland Eskimos * These Eskimos consume a diet largely 
composed of cold water fish, which are rich in EPA. It 
has also been reported that Greenland Eskimos have a low 
incidence of cardiovascular disease and myocardial 
infarction (Editorial, Lancet/ 1983/ Bang and Dyerberg, 
1972; Dyerberg and Sang 1982? Sinclair, 1984). (Kromhout 
et al., 1985) reported an inverse relation between fish 
consumption and a 20 year mortality from coronary heart 
disease.
Needleman et al. / (1979) demonstrated that EPA/ the fatty 
acid precursor of the 3 series prostaglandin (PG) family, 
was enzymatically converted by human platelets into
thromboxane A^ or by blood vessel microsomes Into 
17-prostacyclin (PGI^). The 3 series -.andoperoxide and 
thromboxane weira leas potent than (Nasdleman
et a.I./ 1977). Comparative studief of the actions of 
metabolites of AA and rpa on platelets iv\ platelet rich 
plasma produced unexpected results. Arachidonate, PGH^ 
and thromboxane A^ were potent aggregators of human 
platelets l»t, in Share contrast, the BPA, P6H, and 
TXA^ did not cause platelet aggregation (Raz et al.,
1977) (The actions of the end products of AA and SPA 
metabolism is summarized in Table 1.1.). This latter 
observation was given potential physiological perspective 
by the finding that Eskimos who have a bleeding tendency 
have elevated BPA and depressed AA in platelets (Dyerberg 
et al./ 1978). Xt was suggested that endogenous PGl^ 
synthesis from BPA by the vasculature contributed to the 
bleeding tendency (Dyerberg et al ., 1978j Fisher and 
Weber/ 1984). However/ it was shown that exogenous AA 
could aggregate Eskimo platelets (Dyerberg and Bang/ 
1979b), Although this demonstrates that cyclooxygen&ae 
and thromboxane synthetase are still functional/ it does 
not necessarily refute their assumption that elevated 
PGIg levels are responsible for the lack of 
aggregation, increased PGI^ levels would increase 
platelet cAMP levels, which would prevent aggregation 
regardless of the stimulus i.e. AA as well as ADP. 
Whitaker et al., (1979) and Needleman et al., (1982)
#observed that EPA inhibits platelet aggregation even when 
simultaneously added with the agonist (eg * arachidonate f 
ADP or collagen) or when added before stimulation of 
platelets (Gryglewaki et al, t 1979). Needleman 
et al. /(1979) have also demonstrated that 14c- 
EPA-labelled platelets stimulated with thrombin and 
intact/ prelabelled, perfused kidneys stimulated with 
bradykinin will readily deacylate the prelabelled lipid 
and release EPA. 'thus/ no apparent distinction between 
EPA or AA release from t i s su e  lipids exists, previous 
experiments in platelets (Bills et al .< 1976) have 
demonstrated that agonist stimulation is selective in its 
release of fatty acids (including ole&te, linoleate and 
palmitate)♦ Since EPA acts as a competitive antagonist 
for AA/ the simultaneous release of these fatty acids 
should effectively suppress AA conversion to its 
aggregatory metabolites. The lowering of endogenous AA 
and increase in EPA which must result from a diet of the 
type that the Greenland Eskimos ingest would be 
anticipated to markedly reduce the generation of PGH2 
and thromboxane A^ which cause aggregation. (Needleman 
et al ♦ / 1982)* Dietary trials to test the above 
hypothesis are discussed in Chapter 6*
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2. Aims of: whe present study
Wyndham (1978) found South African whites to have the 
highest death rate from coronary heart disease in the 
Western World* The reasons for this high death rate are 
not clear* One important factor could tie an upset in the 
TXA^ ~ PGI2 balance favouring platelet aggregation and 
thus predisposing to thrombus formation.
In general the aim of this study was to explore selective 
manipulation of prostaglandin metabolism with a view to 
reduci ny the synthesis and/or formation of thromboxane 
A^ with minimal effect on prostacyclin synthesis. To 
this end the following specific studies were undertaken:
a) Pharmacological
i) The effects of normal platelets on aspirin
inhibited platelets in human subjects and to assess 
the relevance of this effect to dosage frequency*
ii) The effect of 20mg aspirin daily on platelet 
function and TXA^ production, 
iii) The effect of low dose aspirin on platelet 
function in Familial Hypercholesterolaemia
b) Dietary
i) The effects of a mixture of fish rich in EPA other 
than mackerel or salmon., on platelet function, 
platelet fatty acid composition and serum lipids.
ii) The effects of a vegetarian diet on platelet 
function and platelet fatty acid composition,
iii) The effects of a dietary supplementation with an 
extract of fish oil (MaxBPA) on platelet function 
platelet fatty acid composition and serum lipids*
CHAPTER
MATERIALS AND METHODS
3.1 Materials
3.1.1. chemicals and Reagents
The source of chemicals and reagents employed in this 
study is listed in Table 3.1. All chemicals were of 
analytical reagent quality unless stated.
Chemicals and reagents
Table 3.1 Sources of Chemicals and reagents used
Source
Merck
British Drug House, {BDH) 
Merck
Mavbaker (SA)
Sigma Chemical Company 
Metck
Amersham International 
Supelco Inc.
BDH
Merck
Hormon-Chemie Munchen 
Merck
Mejrck '
BDH
SAAR Chemicals
Acetone
ADP
Chloroform 
Epinephrine 
Arachidonic Acid 
Benzene
Beta-thromboglobulin Kit
Boron trifluoride-methanol
Calcium chloride
Carbon tetrachloride
Collagen
Dextrose
Disodium hydrogen
orthophosphate
EDTA
Ethanol
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Table 3.1 continued
Chemicals and reagents
Patty acid methyl esters 
(standards) 
formalin 
Hexane 
HCI,
Indomethacin
Malondialdehyde tetrae thyl- 
acefcal 
Magnesium chloride 
Max BPA 
Methanol
Monosodium phosphate 
Nitrogen 
Perchloric acid 
Potassium chloride 
Potassium dihydrogen 
orthophosphate 
Potassium hydroxide 
Repeloote
Silar 10c (10%) on chromosorb 
WD MCC (60-80) Mesh 
Sodium bicarbonate 
Sodium carbonate 
Sodium chloride
Source 
Supelo Inc
SAIMR (Commercial grade) 
Merck
SAAR Chemicals 
MSD Pharmaceuticals
Merck
GD Se&rle (SA)
British cod liver oils
Merck
SDH
Afrox '
Merck
BDH
BDH
BDH
SMM Chemicals 
Applied Science Labs
GD Searle Ltd 
SAAR Chemicals 
SMM Chemical
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Table 3* X continued
Chemicals and reagents Source
SP222-PS on 100/120 support 
Thiobarbituric ac d 
Thromboxane »2 ria kit 
Trichloroacetic acid 
Trisodium citrate
Supelco Inc,
Merck
New Bngland Nuclear 
Merck
SMM chemicals
3.2 Methods
3.2.1 sample Collection and processing 
Venous blood was collected into polyethylene tubes 
containing 1 ml 3.8% sodium citrate per 9 ml blood for 
platelet function studies and into plain glass tubes for 
the lipid estimations* Platelet rich plasma (PRP) for 
aggregation otudies, was prepared by centrifuging the 
blood at !8Qg for 10 minutes(M8E Mistral 6k). Platelet 
poor plasma (p p p) was prepared by centrifuging the 
remaining red cell fraction and small amount of plasma 
(after the PRP had been removed) at 1800g for 15 
minutes* Platelet counts were performed using a 
Thrombocounter C (Coulter Electronics). The platelet 
counts were adjusted with autologous PPP to 250 + 10 x 
109 per itre. Serum lipids measured included high
•?
density lipoprotein (HDk) cholesterol,total cholesterol 
(TO)/ low density lipoprotein (LDL) cholesterol and 
total triglyceride (TRG)
3.3 Platelet aggregation
Platelet aggregation was measured by the method of 
Born and Cross (1963) using a Payton Dual Channel 
aggregation module attached to an SP-U5V recorder and a 
Chronolog Dual channel aggregometer attached to a 
Coulter Electronics omniscribe recorder. Aggregations 
were carried out within 2 hour? of collection. Cuvettes 
were stirad at 1000 rpm, and a constant temperature of 
37 degrees C was maintained. During aggregations, 
platelet rich plasmas were kept in polyethylene tubes 
(15 mm diameter) that were capped at all times when not 
in use. fhe aggregating agents used were 
adenosine-5-diphosphoric acid trilithium salt (ADP)
(0»5-lO.OuM), epinephrine (EPI) (0.14«55uM), collagen 
(1-4 ug/ml) and arachldonic acid (Ah) (0.2-lmM), 
Concentrations in parentheses refer to the final 
concentration in the cuvette, fhe lowest concentration 
of agonist required to produce maximum aggregation was 
determined for each agonist on each occasion that the 
patients were tested. All studies were carried out in 
glass cuvettes that were siliconized for 20 minutes in a 
solution of 10% Repelcote water repellant in 90% carbon 
tetrachloride.
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3 * 3* 1 The variability of platelet aggregation
Experience has shown that? as with any technical
procedure* a certain amount of variability is inherent
in the procedures associated with aggregation studies
using the turbidometric method (Newhouse and Clark?
1978}» The recognition of specific variables/ their
significancet and the means of eliminating or 
controlling the® are vital it meaningful comparative
data are to be obtained* In this section, an attempt
was made to evaluate the known factors influencing
platelet aggregation and the steps taken to eliminate or
control them are discussed,
3*3*1.1. fhe effect of anticoagulants and sodium citrate 
concentrations
Anticoagulants most frequently utilised in coagulation 
studies include sodium citrate/ heparin, 
ethylenediaminetetracetic acid (BPTA)/ and sodium 
oxalate (Newhouse and Ciark,1978) Sodium oxalate and 
KOTA can initially bo omitted from use- in aggregation 
studios because sodium oxalate has previously been shown 
to increase the lability of the procoagulants present in 
the blood (Davidson and Henry/ 1969)/thus making it 
unsuitable for samples prepared for aggregation, and 
RD'X'A has been shown to have adverse effects upon 
platelets (Newhouse & Clark/ 197U).
Anticoagulant activity ia generally mediated through the 
interaction of free calcium iona in the blood, and 
calcium must bo present in PRP for platelet aggregation 
to occur . Aggregation is enhanced as the concentration 
of Ga present in the plasma Increases. Therefore 
anticoagulant solutions that bind calcium ions 
excessively must be avoided. Both BD'JCA and high 
concentrations of sodium citrate have been shown to 
inhibit aggregation by excessive binding of Ca++ 
(Newhouse and Clark, 1976), When heparin is utilized in 
the preparation of PRP, smuj.l platelet aggregates are 
often found unless special care is taken in mixing and 
handling the sample (Zucker, 1974).
In the present study, sodium citrate was used as the 
anticoagulant and the concentration of 3.8% was kept 
constant at all times,
3.3.1.2. Centrifugation and cellular contamination 
Centrifugation auould ensure that in PRP the maximum 
number of platelets ia retained without any red or white 
cell contamination and that in PPP the plasma ia as 
platelet free as possible. Obviously the speed and time 
of <“ >ntrifugation from one sample to the next must be 
kept constant if reproducibility ia to be maintained.
In the present study PRP was obtained by centrifuging 
the blood sample at ISOg for 10 mir and PPP was obtained 
by centrifuging at lBQGg tor 15 minutes.
3-.3.1.3, Platelet concentration
The initial optical density of the PUP is directly 
dependent upon the platelet concentration {Orenburg* 
1970)* As this concentration increases, the platelets 
in the cuvette become more closely packed togethert 
increasing the possibility of collision and thus the 
rat® of aggregation (Hixma,1972). Cronberg (1970) 
reported that although the increase in.platelet 
concentration may produce qualitative differences,the 
actual atickiness of the platelets was not changed with 
variable concentrations, Differences in the appearance 
of the stcyndary phase of ADP induced aggregation f 
however, were noted .in studies by Danta (2970). At low 
platelet counts the secondary phase, because of its 
diminished slope# tends to be obscured by the primary 
wave of aggregation and thus appears to be absent. 
Therefore, standardization of the platelet count by 
dilution of the PRP with autologous PPP is often 
performed.
In the present study all platelet counts were adjusted 
using autologous PPP to 250 + 10 x It)9 per litre.
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3.3.1.4 Effect, of time
The stability of PRP in relation to storage time after 
collection was found to vary from patient to patient/ 
and from day to day in the same patient (Harrison 
et al,,1967 ) .They reported that aggregation responses of 
some platelet rich plasmas tend to remain stable up to 3 
hours after collection/ while others become 
progressively less responsive as time progresses.
Warlow et al., (1974)/ suggested that the interval 
between venepuncture and measurement of platelet 
aggregation should be fixed and should be stated with 
all data obtained,
in the present study/ aggregations were commenced 
immediately after preparation of the PRP and PPP and 
completed within two hours of collection,
4.3.1.5, Effect oi pH change
.Mwiinm m i i n  '« i i— Mrt-nry..!' i k .ih  !■» !«■  in u«y. r — ■!»».
Changes in the pH Era known to have profound effects 
upon the aggregating properties of the platelets. 
Generally/ aggregation is not observed below a pH of 6*4 
or above a pH of 10, Maximal aggregation is considered 
to occur at or near pH 8 (Skoza et al., 1967). Changes 
in the plasma pH are brought about as a result of 
preparation for aggregation studies, time being a vital 
factor. After centrifugation to separate PRP the 
resulting pH of the plasma is about 7,5. Longer
. .  mm Jtet
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centrifugation to obtain PPP and the addition of this 
PPP to PRP to standardize the count yields a pH of about 
7,6 for f » beginning of aggregation studies providing 
ti-n.t the plasma preparations have taken place within 
.hrs,- (Collor et al., 1976) . Continued changes in pH 
with time are mediated by the rate at which C02 
diffuses out of the plasma system into the ambient 
atmosphere. Factors affecting this rate of diffusion 
and subsequent rise in pH include; (1) the surface area 
to volume ratio of the plasma (2) whether the plasma is 
capped or uncapped while standing# and (3) how 
frequently the plasma i# mixed (Kerby & Taylor, 1971).
In the present stady the PRP and PP1> were, prepared 
immediately after blood collection and stored in 
polyethylene tubes (15mm diameter), The t - were 
capped at all times when not in use and in fcnar.wijen 
aggregations. The tubes were mixed by gen r vy inversion 
once ©very 15 minutes to prevent platelets fffoxs 
settling,
3.3.1.6. Effects of temperature 
The temperature at which PRP is stored prior to 
aggregation studies and the temperature at which the 
actual aggregation is performed has a significant 
influence upon the rate and extent of aggregation
- -  jmm J*,
achieved by the plasma preparation. Platelets stored at 
room temperature may be relatively stable for the first 
two hours. However, platelets stored at 37 degrees C 
will, in this time, have lost thiir responsiveness 
(O’Brien, 1964). Lower temperatures, 0-4 degrees C, 
maintain aggregation ability for even longer periods of 
time. However, the major problem associated with the 
storage of plasma samples at progressively lower 
temperatures is the increased tendency towards 
spontaneous aggregation (Anstall and Hawkey, 1962).
In the present study, PRP w & a stored at room temperature 
prior to commencement of aggregation studies. All 
aggregation studies were performed at 37 degrees c.
3.3.1.7. Effects o f stirring and stir bar size 
Stirring the PRP with the selected aggregation agent is 
necessary for the subsequent aggregation to occur.
This stirring process potentiates platelet collisions 
and thus aggregate formation (Born and Cross, 1963).
The rate at which aggregation proceeds could be within a 
specific range of rpm, directly related to the rate of 
stirring, with the rate and extent of aggregation 
increasing as the stirring increases (Mustard and 
Packam, 1970). Significant changes in aggregation do 
not occur when stir speed is varied from 600 - 1200 
rmp. When stir speed is reduced below 600 rpm,
a reduction is noted in the rate and extent of 
aggregation. When the stir speed is increased above 
1200 rpm, increased disaggregation is evident (Sixma,
1 9 7 2 ) .  Maximum aggregation is produced at an optimal 
stir speed of 1 000 rpm (O'Brien# 1 9 6 2 ) .  Coller and 
Gralniek ( 1 9 7 6 )  have shown that the width, length and 
toughness of the stir bars are associated with the 
ability of che stir bar to mix the PRP and the 
aggregating agent completely and efficiently.
In the present study, aggregations were performed with 
constant stirring at I 000 rpm. Stir bars used for the 
aggregation studies were teflon coated and uniform in 
size.
3.3.2 The quantitation of platelet aggregation
In the present study/ drug arid dietary effects on 
p l a t e l e t  function were studied and major aggregation 
changes were sought. The clinical significance of 
slight changes is questionable. The parameters used to 
e v a l u a t e  aggregation ware; a) the lowest concentration of  
agonist required to produce a maximum aggregation response, 
b) the height o f  the aggregation curve, measured in centimeters.
Maximum aggregation response was defined as the maximal
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change in light transmittance at an interval 5 minutes 
after the onset of aggregation. This method of 
assessing platelet aggregation was also used by Carvalho 
et al., (1974).
3.4. Malondlaldehyde (MPA) Estimations 
MD& production in platelets after aggregation was 
determined by a modification of the methods of Stuart 
et al., (1975) and McMillan et al. 1977. Sodium 
arachidonate was used as the agonist to induce platelet 
aggregation.
Sodium arachidonate was prepared as described by
Kinlough Rathbone et al. (1976).Arachidonie acid (hk) 50
mg was dissolved in 3.2 ml benzene to yield a 50 mM
solution. The mixture was aliquotted into 0.3 ml
quantities and stored at -20 degrees C. Before use the
benzene was evaporated under nitrogen gas and replaced
with 0.3 ml of 0.1 M NaCCU.3
MDA standards using maiondialdehyde tetraethylacetal 
were prepared in the following way: a 0*01 molar 
solution was made (0.22g MDA-tetraethylacetal dissolved 
in 200 ml distilled water) and labelled as MDA stock 
solution. The stock solution was then diluted to yield 
standard concentrates of 2.0, 2.5, 5,8 and 10 nmoles/20 
ul. A 0.53 % solution of 2-thiobarbituric acid was
prepared in 2.3% perchloric acid and stored at 4 degrees 
C. tphe solution was prepared by dissolving 800 mg of 
2-'thiobarbituric acid in 20 ml concentrated NaOH to 
which 50 ml of distilled water was then added. The pH 
of the solution was adjusted by the addition of 
concentrated perchloric acid and the volume then brought 
to 100 ml with distilled water. Fifty ml 7% perchloric 
acid was added to this 100 ml solution (Stuart et al., 
1975), The MDA standards were then used to construct a 
standard curve in the following way: 20 ul of MDA 
standards(2/ 2*5/ 5/ 8 and 10 nmoles/20 ul) were added 
to 200 ul PRP (PEP adjusted to 250 + 10 x 10/9 per 
litre with autologous PPP (see section 4*2.2) Blanks 
without added MDA were also prepared using 200 ul PRP 
and 20 ul saline. Proteins were precipitated by adding 
an equal volume of 100 % trichloroacetic acid, and after 
centrifugation (1 200g for 5 minutes at room 
temperature ) 200 ul volumes of the protein free 
supernatants were mixed with equal volumes 0»53% 
thiobarbituric acid. Samples were incubated for 30 
minutes at 70 degrees C with a marble condenser on each 
tube, allowed to cool at room temperature, and mixed 
with 0*6 ml glass-distilled water. MDA was measured by 
recording absorbance at 532 nm in a Pye-Unicam SP2800 
spectrophotometer. Cells of 1 cm path length were used.
Author Chetty N
Name of thesis Drug and dietary modification of platelet function 1985
PUBLISHER:
University of the Witwatersrand, Johannesburg  
©2013
LEGAL NOTICES:
Copyright Notice: All materials on the U n i v e r s i t y  o f  t he  W i t w a t e r s r a n d ,  J o h a n n e s b u r g  L i b r a r y  website 
are protected by South African copyright law and may not be distributed, transmitted, displayed, or otherwise 
published in any format, without the prior written permission of the copyright owner.
Disclaimer and Terms of Use: Provided that you maintain all copyright and other notices contained therein, you 
may download material (one machine readable copy and one print copy per page) for your personal and/or 
educational non-commercial use only.
The University o f the W itw atersrand, Johannesburg , is not responsible for any errors or omissions and excludes any 
and all liability for any errors in or omissions from the information on the Library website.
